gmi-1687

GMI-1687 is a highly potent, second-generation small molecule E-selectin antagonist developed by GlycoMimetics. It is designed for subcutaneous administration and demonstrates full bioavailability via this route. GMI-1687 inhibits E-selectin, a cell adhesion molecule that mediates the attachment of inflammatory cells to blood vessel linings—a process implicated in the pathogenesis of vaso-occlusive crises (VOCs) in sickle cell disease (SCD). By blocking E-selectin, GMI-1687 aims to prevent or reduce VOCs by impeding the formation of clots that obstruct blood flow and oxygen delivery. The drug has also been investigated as an antineoplastic and antithrombotic agent. Clinical development has focused on SCD-related VOCs and inflammation, with preclinical work in multiple myeloma[1][2][3][4][5][6].